title: [Nursing care for ovarian cancer patients with intraperitoneal chemotherapy].
abstract: Ovarian cancer, known as a "silent killer", is the leading cause of gynecologic cancer death. Standard treatments for ovarian cancer are debulking surgery combined with platinum chemotherapy drugs to prolong the survival of patients. According to clinical trials run by the American Society of Gynecologic Oncology, patients who received intraperitoneal (IP) chemotherapy survived longer on average than patients who received intravenous chemotherapy alone. Thus, intraperitoneal chemotherapy is a new potential approach for treating ovarian cancer patients. However, the toxicities and undesirable complications of IP chemotherapy are the major challenges of this treatment approach. This article helps nurses recognize the toxicities and complications of IP chemotherapy and may be used as reference for future revisions to patient care guidelines.
authors: Department of Nursing, National Taipei University of Nursing and Health Sciences, Taiwan, ROC. yuyin@ntunhs.edu.tw.
authors: Yu-Ying
authors: YY
authors: Lu
authors: Department of Nursing, Mackay Memorial Hospital, Taiwan, ROC.
authors: Ju-Fen
authors: JF
authors: Chou
authors: College of Nursing, and Vice President, National Taipei University of Nursing and Health Sciences, Taiwan, ROC.
authors: Lee-Ing
authors: LI
authors: Tsao
authors: Department of Nursing, National Taipei University of Nursing and Health Sciences, Taiwan, ROC.
authors: Shu-Yuan
authors: SY
authors: Liang
authors: Department of Nursing, National Taipei University of Nursing and Health Sciences, Taiwan, ROC.
authors: Shu-Fang
authors: SF
authors: Wu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000451:nursing*
chemical_list: D000970:Antineoplastic Agents
keywords: debulking; intraperitoneal chemotherapy; ovarian cancer